Patents Represented by Attorney, Agent or Law Firm A. Dean Olson
-
Patent number: 8263623Abstract: The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.Type: GrantFiled: July 1, 2009Date of Patent: September 11, 2012Assignee: Pfizer Inc.Inventors: Lyn Howard Jones, Dannielle Frances Roberts, Ross Sinclair Strang
-
Patent number: 8178558Abstract: This invention relates to novel substituted pyridylmethyl bicyclocarboxamide compounds and to their use in therapy. These compounds are particularly useful as modulators of the VR1 (Type I Vanilloid) receptor, and are thus useful for the treatment of pain, neuralgia, neuropathies, nerve injury, burns, migraine, carpal tunnel syndrome, fibromyalgia, neuritis, sciatica, pelvic hypersensitivity, bladder disease, inflammation, or the like in mammals, especially humans.Type: GrantFiled: September 10, 2007Date of Patent: May 15, 2012Assignee: Pfizer Inc.Inventors: Satoshi Nagayama, Yuji Shishido, Hirotaka Tanaka
-
Patent number: 8178699Abstract: Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.Type: GrantFiled: July 30, 2008Date of Patent: May 15, 2012Assignee: Pfizer Inc.Inventors: Eric C Anderson, Ronald J Biediger, Jie Chen, Brian Dupre, Pedro Lory, Robert V. Market, Keith A. Monk, Michael M. Savage, Reginald Tennyson, Brandon M. Young
-
Patent number: 8158650Abstract: This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: October 11, 2007Date of Patent: April 17, 2012Assignee: Pfizer Inc.Inventors: Koji Ando, Hirotaka Tanaka
-
Patent number: 8134004Abstract: This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: July 2, 2007Date of Patent: March 13, 2012Assignee: Pfizer Inc.Inventors: Tadashi Kawashima, Satoshi Nagayama, Kazunari Nakao, Hirotaka Tanaka
-
Patent number: 7129234Abstract: The invention relates to compounds of formula IType: GrantFiled: November 25, 2003Date of Patent: October 31, 2006Assignee: Pfizer Inc.Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Jr., Donald S. Middleton, Alan Stobie
-
Patent number: 6784185Abstract: Compounds of general formula I: or pharmaceutically or veterinarily acceptable salts, solvates, polymorphs or pro-drugs thereof wherein: wherein R1, R2, R3, R4, X and A have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.Type: GrantFiled: March 14, 2002Date of Patent: August 31, 2004Assignee: Pfizer Inc.Inventors: Charlotte Moira Norfor Allerton, Christopher Gordon Barber, Mark Ian Kemp
-
Patent number: 6770645Abstract: Compound of general formula I: wherein R1, R2, R3, R4, X, Y and R5 have the meanings given herein which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.Type: GrantFiled: March 12, 2002Date of Patent: August 3, 2004Assignee: Pfizer Inc.Inventors: Stephen Martin Denton, Mark Ian Kemp, Sandra Dora Newman, David James Rawson
-
Patent number: 6683080Abstract: Use of vardenafil or a pharmaceutical composition thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of type 2 diabetes mellitus.Type: GrantFiled: January 30, 2002Date of Patent: January 27, 2004Assignee: Pfizer Inc.Inventors: David A. Fryburg, Earl M. Gibbs, Nandan P. Koppiker
-
Patent number: 6660756Abstract: The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2 R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.Type: GrantFiled: March 12, 2002Date of Patent: December 9, 2003Assignee: Pfizer Inc.Inventors: Stephen Challenger, Andrew Simon Cook, Adam Thomas Gillmore, Donald Stuart Middleton, David Cameron Pryde, Alan Stobie
-
Patent number: 6630504Abstract: The invention provides compounds of general formula (I) wherein R1 is H or C1-C6 alkyl; R2 and R3, together with the interconnecting atoms form a 4 to 8-membered saturated ring containing one or two heteroatoms (including the nitrogen to which R2 is attached) wherein a second heteroatom, if present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring cannot contain two adjacent heteroatoms; Z is CF3, OCF3, C1-C6alkylthio or C1-C6alkoxy; Y is hydrogen, halogen, —ORa, Ra or C1-C6alkylthio, and wherein Ra is C1-C4 alkyl optionally substituted with fluorine atoms; or when Z and Y are attached para and meta to the ether linkage linking rings A and B, Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring which may be saturated, unsaturated or aromatic, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected froType: GrantFiled: August 24, 2001Date of Patent: October 7, 2003Assignee: Pfizer Inc.Inventors: Mark David Andrews, David Hepworth, Donald Stuart Middleton, Alan Stobie
-
Patent number: 6610747Abstract: A compound of general formula (I) wherein R1 and R2 are H, C1-C6alkyl or (CH2)d(C3-C6cycloalkyl) wherein d=0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached form an azetidine ring; Z or Y is —SR3 and the other Z or Y is halogen or —R3; wherein R3 is C1-C4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from oxygen, sulfur and nitrogen; R4 and R5, which may be the same or different, are: A—X, wherein A=—CH═CH— or —(CH2)p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR6R7, SO2NR6R7, SO2NHC(═O)R6, OH, C1-4alkoxy, NR8SO2R9, NO2, NR6R11, CN, CO2R10, CHO, SR10, S(O)R9 or SO2R10; or a 5- or 6-membered hetType: GrantFiled: August 27, 2001Date of Patent: August 26, 2003Assignee: Pfizer Inc.Inventors: Mavis Diane Adam, Mark David Andrews, Mark Leonard Elliott, Geoffrey Edward Gymer, David Hepworth, Harry Ralph Howard, Jr., Donald Stuart Middleton, Alan Stobie
-
Patent number: 6586448Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: October 10, 2000Date of Patent: July 1, 2003Assignee: Pfizer Inc.Inventors: Michael P. DeNinno, George T. Magnus-Aryitey, Roger B. Ruggeri, Ronald T. Wester
-
Patent number: 6537987Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents or anti-acne agents.Type: GrantFiled: December 18, 1998Date of Patent: March 25, 2003Assignee: Pfizer Inc.Inventors: Ernest S. Hamanaka, Cheryl M. Hayward
-
Patent number: 6492401Abstract: NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.Type: GrantFiled: August 18, 1999Date of Patent: December 10, 2002Assignee: Pfizer, Inc.Inventors: Ernest S. Hamanaka, Angel Guzman-Perez, Roger B. Ruggeri, Ronald T. Webster, Christian J. Mularski
-
Patent number: 6492412Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: June 29, 2001Date of Patent: December 10, 2002Assignee: Pfizer, Inc.Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
-
Patent number: 6489478Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: September 27, 2000Date of Patent: December 3, 2002Assignee: Pfizer Inc.Inventors: Michael P. DeNinno, George T. Magnus-Aryitey, Roger B. Ruggeri, Ronald T. Wester
-
Patent number: 6395751Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: September 27, 2000Date of Patent: May 28, 2002Assignee: Pfizer Inc.Inventors: Michael P. DeNinno, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
-
Patent number: 6362198Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: September 27, 2000Date of Patent: March 26, 2002Assignee: Pfizer Inc.Inventors: Steven W. Goldstein, Michael R. Makowski, Roger B. Ruggeri, Ronald T. Wester
-
Patent number: 6310075Abstract: Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.Type: GrantFiled: September 27, 2000Date of Patent: October 30, 2001Assignee: Pfizer Inc.Inventors: Michael P. DeNinno, Roger B. Ruggeri, Ronald T. Wester